Wang (2020)
15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: an ambispective observational cohort study
32328724
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176814/
Treatment
Treatment for COVID-19 (Treated with Lopinavir–Ritonavir vs. Not received)
COVID-19 (death)
Hazard ratio: 0.350 (0.150-0.830) Adjusted model

China

Ambispective Observational Study

Medical records

548

548 hospitalized COVID-19 patients

none

Total

15 Day


COVID-19 (death)

78

Death within 15 days of hospitalization.


Treatment

Treatment for COVID-19

Lopinavir/ritonavir was associated with decreased mortality.

Not received

Treated with Lopinavir–Ritonavir


Hazard ratio

0.350 (0.150-0.830)

Yes

No

Yes

Risk was adjusted for Age, oxygen saturation (SaO2), WBC, Lymphocyte (count and time), LDH, and multiorgan dysfunction, Glucocorticoid treatment, lopinavir/ritonavir treatment, arbidol treatment, ribavirin treatment.


14.2% patients of this cohort reached the primary endpoint of death within 15-day hospitalization. Aging, hypoxia, lymphopenia, high LDH level and multiple organ dysfunction were associated with increased 15-day in-hospital mortality from COVID-19. Lopinavir/ritonavir was associated with decreased mortality. Among the critically ill patients, the hazard ratio was not reduced in those receiving invasive ventilation versus non-invasive ventilation.

Good

Yes